Dr Hideaki Miyake

After graduating from Kobe University Graduate school of Medicine, Dr. Miyake joined the Vancouver Prostate Centre as a postdoctoral fellow in 1998. He worked with Dr. Martin Gleave investigating the molecular mechanisms involved in the progression of prostate cancer to androgen-independence and the development of a novel therapeutic strategy targeted against antiapoptotic genes using antisense oligonucleotide technology. To date, he has published more than 300 peer-reviewed papers, including 46 under joint authorship with Dr. Gleave. He is a recipient of many awards, such as the First prize in the Essay Contest at the CUA annual meeting in 1999, First prize in the Essay Contest at the AUA annual meeting in 2000 and Best Paper Award of the Clinical Section at the JUA annual meeting in 2008.

Dr. Miyake’s current research focuses on a wide range of topics associated with urological oncology, including the role of inflammatory cytokines as activators of androgen receptor, the impact of the prostate's microenvironment on local aggressiveness of prostate cancer and the overcoming of acquired resistance of renal cancer to molecular targeted agents. Moreover, he has tried to develop novel therapies for urological cancers by combining conventional therapeutic modalities and OGX-011, an antisense oligonucleotide inactivating the cytoprotective chaperon clusterin, in collaboration with Dr. Gleave.

Dr. Miyake is currently playing a central role in the Division of Urology, Kobe University Hospital as a clinical scientist and urologic surgeon. Therefore, he is also performing a number of clinical studies focusing on a wide variety of interesting topics, such as the development of extended radical prostatectomy for locally advanced prostate cancer, the improvement of functional outcomes in bladder cancer patients with orthotopic neobladder and the assessment of useful sequential therapy for metastatic renal cancer using molecular targeted agents. In addition, as the Chair of the Urological Oncology Group at Kobe University Hospital, he provides access for patients with urological cancer to the latest clinical trials using novel drugs.